Spark Therapeutics has sold a priority review voucher, entitling the holder to a faster six-month FDA drug review, to Ireland’s Jazz Pharmaceuticals for $110m, a fraction of the price these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback